Breast Cancer Research and Treatment

, Volume 117, Issue 3, pp 603–609

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

  • Stephanie L. Hines
  • Betty Mincey
  • Todor Dentchev
  • Jeff A. Sloan
  • Edith A. Perez
  • David B. Johnson
  • Paul L. Schaefer
  • Steve Alberts
  • Heshan Liu
  • Stephen Kahanic
  • Miroslaw A. Mazurczak
  • Daniel A. Nikcevich
  • Charles L. Loprinzi
Clinical Trial

Abstract

Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized to upfront or delayed zoledronic acid 4 mg every 6 months. Patients in the delayed arm were only given zoledronic acid if they developed a post-baseline BMD T score <−2.0 or had a fracture. The primary endpoint was the mean percent change in lumbar spine (LS) BMD at 1 year. About 558 women enrolled; 395 provided 1 year BMD data. The upfront arm experienced a mean change of +3.66% in LS BMD versus -1.66% for the delayed group (P < 0.001). Changes at the femoral neck/total hip were also greater for the upfront versus delayed arms (P < 0.001; P < 0.001) with differences persisting at 2 years. Patients in the delayed arm were more likely to experience a clinically meaningful 5% loss of BMD at all sites versus the upfront zoledronate group. Patients in the upfront arm were slightly more likely to report limb edema, fatigue, fever, nausea and jaw osteonecrosis(1%). Upfront zoledronic acid prevents bone loss in postmenopausal women with BC starting letrozole after tamoxifen.

Keywords

Breast cancer Aromatase inhibitor Bone loss Zoledronic acid 

References

  1. 1.
    Perez EA, Weilbaecher K (2006) Aromatase inhibitors and bone loss. Oncology 20(9):1029–1039PubMedGoogle Scholar
  2. 2.
    Powles T, Hickish T, Kanis JA, Tidy A, Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14(1):78–84PubMedGoogle Scholar
  3. 3.
    The ATAC Trialists’ Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 98(9):1802–1810. doi:10.1002/cncr.11745 CrossRefGoogle Scholar
  4. 4.
    The ATAC Trialists’ Group (2005) Results of the ATAC trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62. doi:10.1016/S0140-6736(04)17666-6 CrossRefGoogle Scholar
  5. 5.
    Goss PE, Ingle JN, Martino S, Robert JN, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802. doi:10.1056/NEJMoa032312 PubMedCrossRefGoogle Scholar
  6. 6.
    Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092. doi:10.1056/NEJMoa040331 PubMedCrossRefGoogle Scholar
  7. 7.
    Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret MJ, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG1–98. J Clin Oncol 25(5):486–491. doi:10.1200/JCO.2006.08.8617 PubMedCrossRefGoogle Scholar
  8. 8.
    The Breast International Group (BIG) 1–98 Collaboratie Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757. doi:10.1056/NEJMoa052258 CrossRefGoogle Scholar
  9. 9.
    Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination trial. J Bone Miner Res 21(8):1215–1223. doi:10.1359/jbmr.060508 PubMedCrossRefGoogle Scholar
  10. 10.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA. 17. J Clin Oncol 24(22):3629–3635. doi:10.1200/JCO.2005.05.4882 PubMedCrossRefGoogle Scholar
  11. 11.
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346(9):653–661. doi:10.1056/NEJMoa011807 PubMedCrossRefGoogle Scholar
  12. 12.
    Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25(7):829–836. doi:10.1200/JCO.2005.05.3744 PubMedCrossRefGoogle Scholar
  13. 13.
    Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194. doi:10.1359/JBMR.050304 PubMedCrossRefGoogle Scholar
  14. 14.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Chung Leung P, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue T, Sellmeyer D, Fink Eriksen E, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. doi:10.1056/NEJMoa067312 PubMedCrossRefGoogle Scholar
  15. 15.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280(24):2077–2082. doi:10.1001/jama.280.24.2077 PubMedCrossRefGoogle Scholar
  16. 16.
    Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135. doi:10.1007/s00223-003-0042-4 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Stephanie L. Hines
    • 1
  • Betty Mincey
    • 2
  • Todor Dentchev
    • 3
  • Jeff A. Sloan
    • 4
  • Edith A. Perez
    • 1
  • David B. Johnson
    • 5
  • Paul L. Schaefer
    • 6
  • Steve Alberts
    • 4
  • Heshan Liu
    • 4
  • Stephen Kahanic
    • 7
  • Miroslaw A. Mazurczak
    • 8
  • Daniel A. Nikcevich
    • 9
  • Charles L. Loprinzi
    • 4
  1. 1.Mayo Clinic JacksonvilleJacksonvilleUSA
  2. 2.Private PracticeJacksonvilleUSA
  3. 3.Altru Health SystemsGrand ForksUSA
  4. 4.Mayo Clinic FoundationRochesterUSA
  5. 5.Wichita Community Clinical Oncology ProgramWichitaUSA
  6. 6.Toledo Community Hospital Oncology Program CCOPToledoUSA
  7. 7.Siouxland Hematology-Oncology AssociatesSioux CityUSA
  8. 8.Sioux Community Cancer ConsortiumSioux FallsUSA
  9. 9.Duluth CCOPDuluthUSA

Personalised recommendations